| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 |
| 29 Oct 2026 | SCHEDULE 13G |
| 03 Sep 2026 | 10-Q |
| 03 Sep 2026 |
8-K: Results of Operations and Financial Condition
Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 |
| 18 Aug 2026 | SCHEDULE 13G |
| 17 Aug 2026 | SCHEDULE 13D |
| 17 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 |
Form 4: 5AM Ventures VI, L.p., 10% owner and 5 others
Received 7,325,962 shares by conversion |
| 12 Aug 2026 |
Form 4: Sanofi, 10% owner
Received 672,778 shares by conversion |
| 12 Aug 2026 | Form 3: Sanofi, 10% owner |
| 11 Aug 2026 |
Form 4: Westlake BioPartners Fund I, L.p., 10% owner and 5 others
Received 12,695,305 shares by conversion |
| 10 Aug 2026 |
Form 4: Foresite Capital Management V, Llc, 10% owner and 5 others
Received 9,041,328 shares by conversion · Bought 140,000 shares ($2.52M) |
| 10 Aug 2026 |
Form 4: Smith Todd N, Director
Granted 105,542 Director Stock Option (right to buy) |
| 10 Aug 2026 |
Form 4: Tananbaum James B., Director
Received 9,041,328 shares by conversion · Bought 140,000 shares ($2.52M) |
| 10 Aug 2026 |
Form 4: Seidenberg Beth C, Director
Received 12,695,305 shares by conversion |
Loading...